New therapeutics are needed to overcome resistance to androgen deprivation therapies.
Castrate-resistant prostate cancer cells are addicted to androgen receptor signaling.
Coactivator recruitment is vital for androgen receptor signaling.
Promising coactivator binding inhibitors have been developed.
These inhibitors retain their activity in castrate-resistant prostate cancer cells.